Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide.
Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide.
复制标题
新型拮抗剂表明 CB1 大麻素受体与 anandamide 的降血压作用有关。
DOI：
10.1016/0014-2999(95)00181-j
复制
发表时间：
1995
影响因子：
5
通讯作者：
Kunos,G
中科院分区：
文献类型：
--
作者：
Varga,K;Lake,K;Martin,BR;Kunos,G
在麻醉的大鼠中，内源性大麻素anandamide具有强大的心血管作用，包括短暂的升压作用和较长时间的抑制反应。在颈脊髓横断或酚妥拉明阻断α-肾上腺素能受体后，抑制反应减弱，并被cb1大麻素受体的选择性拮抗剂剂量依赖性抑制。加压组件不受任何这些干预措施的影响。这表明，抑制反应是由于cb1受体介导的交感神经张力的抑制，而压力成分是由于不涉及相同受体或交感神经系统的外周作用。
In anaesthetised rats, the endogenous cannabinoid anandamide has potent cardiovascular effects that include a brief pressor effect and a more prolonged depressor response. The depressor response is attenuated after transection of the cervical spinal cord or blockade of α-adrenergic receptors by phentolamine, and is dose-dependently inhibited by a selective antagonist of the CB1cannabinoid receptor. The pressor component is not affected by any of these interventions. This suggests that the depressor response is due to inhibition of sympathetic tone mediated by CB1receptors, whereas the pressor component is due to a peripheral action that does not involve the same receptors or the sympathetic nervous system.